Krystal Biotech (KRYS) Cash from Financing Activities (2016 - 2026)

Krystal Biotech has reported Cash from Financing Activities for 11 years, with the latest figure at $15.1 million in Q2 2026.

• Cash from Financing Activities for Q2 2026 came in at $15.1 million, up 738.14% year-over-year; the trailing twelve-month figure through Jun 2026 was $24.0 million (up 591.47% YoY), and the FY2025 annual result was $8.7 million, down 67.78% from the prior year.
• Cash from Financing Activities improved to $15.1 million in Q2 2026, from -$10.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $185.3 million in Q2 2023 and troughed at -$12.5 million in Q1 2025.
• A 5-year average of $15.5 million and a median of $3.2 million in 2022 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2022, when Cash from Financing Activities jumped 15527.14%; it then slumped 217.79% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $3.1 million in 2022, then slipped by 14.66% to $2.6 million in 2023, then slipped by 7.29% to $2.4 million in 2024, then jumped by 545.22% to $15.7 million in 2025, then retreated by 3.91% to $15.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $15.1 million in Q2 2026, -$10.5 million in Q1 2026, and $15.7 million in Q4 2025.